PPBT Key Statistics, Chart & Performance
The current stock price of PPBT is 0.633 USD. In the past month the price decreased by -15%. In the past year, price decreased by -82.12%.
PPBT Technical Analysis
PPBT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PPBT. Both the profitability and financial health of PPBT have multiple concerns.
PPBT Financial Highlights
Over the last trailing twelve months PPBT reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 85.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.32% | ||
| ROE | -9.92% | ||
| Debt/Equity | 0 |
PPBT Forecast & Estimates
PPBT Ownership
PPBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.31B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About PPBT
Company Profile
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Company Info
PURPLE BIOTECH LTD-ADR
4 Oppenheimer St., Science Park
Rehovot 7670104 IL
CEO: Gil Efron
Employees: 9
Phone: 97239333121
PURPLE BIOTECH LTD-ADR / PPBT FAQ
Can you describe the business of PURPLE BIOTECH LTD-ADR?
Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
What is the stock price of PURPLE BIOTECH LTD-ADR today?
The current stock price of PPBT is 0.633 USD. The price decreased by -2.62% in the last trading session.
Does PURPLE BIOTECH LTD-ADR pay dividends?
PPBT does not pay a dividend.
What is the ChartMill technical and fundamental rating of PPBT stock?
PPBT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is PPBT stock listed?
PPBT stock is listed on the Nasdaq exchange.
When does PURPLE BIOTECH LTD-ADR (PPBT) report earnings?
PURPLE BIOTECH LTD-ADR (PPBT) will report earnings on 2026-03-03.